Table 5.
Companion diagnostics and anticancer treatments in hematology.
| Anticancer treatments approved by FDA carrying companion diagnostics | |
|---|---|
| Biomarker with pharmacokinetic effect | TPMT (mercaptopurine, thioguanine) |
| UGR1A1 (irinotecan, nilotinib) | |
| Biomarkers with pharmacodynamic effect | EGFR (cetuximab, erlotinib, gefitinib, panitumumab, afatinib) |
| KRAS (cetuximab, panitumumab) | |
| ABL (imatinib, dasatinib, nilotinib) | |
| BCR-ABL (bosutinib, busulfan) | |
| ALK (crizotinib) | |
| C-kit (imatinib) | |
| HER2/neu (lapatinib, trastuzumab) | |
| ER (tamoxifen, anastrozole) | |
Genes in bold are used for companion diagnostics of the drugs mentioned in the brackets.
Data are obtained from FDA pharmacogenomics website (http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm).